United Therapeutics (NASDAQ:UTHR) CEO Sells $5,393,530.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $567.74, for a total transaction of $5,393,530.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,000,850.62. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Stock Performance

UTHR traded up $10.00 on Tuesday, reaching $578.43. 776,301 shares of the company’s stock were exchanged, compared to its average volume of 478,740. The company’s 50 day moving average is $563.97 and its 200-day moving average is $513.01. The company has a market cap of $24.55 billion, a price-to-earnings ratio of 21.35, a PEG ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the company posted $6.63 EPS. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current year.

Institutional Trading of United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. AE Wealth Management LLC lifted its stake in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC increased its holdings in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc acquired a new position in shares of United Therapeutics during the third quarter valued at $444,000. Tobam raised its holdings in United Therapeutics by 183.9% during the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after purchasing an additional 4,953 shares in the last quarter. Finally, Perpetual Ltd bought a new stake in United Therapeutics during the fourth quarter worth approximately $1,059,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of several research analyst reports. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.